The anaesthetic method for intracranial neurosurgery must provide haemodynamic stability on emergence and allow early evaluation of the neurological status. In this study, we examined the effects of the α-2 agonist dexmedetomidine given at the end of the procedure to prevent hyperdynamic responses during extubation and to allow a comfortable and high-quality recovery.

Forty ASA I–III patients, aged between 18 and 75 yr, having elective intracranial surgery, were divided into two random groups. Standard procedures and drugs were used for monitoring, induction and maintenance. Isoflurane was reduced by 50% 5 min before the end of the surgery, and in Group I dexmedetomidine 0.5 μg kg−1 and in Group II 20 mL of 0.9% NaCl were administrated intravenously over 60 s. Systolic, diastolic and mean arterial pressures, and heart rate were recorded before intravenous administration and also at 1, 3 and 5 min after administration, 1 min before extubation, during extubation, 1, 3, 5, 10, 15, 20 and 30 min after extubation. Duration of extubation and recovery were noted, and the quality of extubation was evaluated on a 5-point scale.

Mean arterial pressure and heart rate were significantly higher in Group II than in Group I (P < 0.01). There were no statistically significant differences between groups regarding the duration of extubation and recovery (P > 0.05). Extubation quality score of all the patients were 1 in Group I; and in Group II, the quality scores were 1 for 35%, 2 for 45% and 3 for 20% of the patients (P < 0.001). None of the patients in Group I and Group II showed respiratory depression, nausea or vomiting.

Without interfering in recovery time, dexmedetomidine 0.5 μg kg−1 administered 5 min before the end of surgery stabilizes haemodynamics, allows easy extubation, provides a more comfortable recovery and early neurological examination following intracranial operations.

The haemodynamic responses during extubation can cause complications afteropen-heart surgery. In this study, we aimed to examine the effect of esmololand magnesium before extubation on these haemodynamic responses.

Following the approval of local Ethics Committee, 120 patients havingcoronary artery bypass grafting with extubation in the intensive care unitwere included in the study. Patients were allocated to receive esmolol 1 mgkg−1 (group I, n = 40), magnesium 30 mg kg−1 (Group II,n = 40) or normal saline (Group III,n = 40). Study medication wasadministered as a 20-min infusion in a volume of 20 mL. Patients wereextubated just after termination of the infusion. Heart rate, blood pressureand central venous pressure were recorded prior to drug administration,before extubation, during extubation and 1 min after extubation.

Heart rate was lower in Group I than in Groups II (P < 0.05) and III (P < 0.001) and lower inGroup II than in Group III (P < 0.05) during extubation. It wasalso lower in Group I than in Group III (P < 0.05) afterextubation. Systolic blood pressure was lower in Group I than in Groups IIand III (P < 0.001) during extubation. Diastolic blood pressurewas higher in Group III than in Groups I and II during extubation (P< 0.001) and after extubation (P < 0.05). Meanarterial pressure was lower in Group I than in Groups II and III (P< 0.001) during extubation, lower in Group II than in Group III(P < 0.05) during extubation and lower in Group I than in GroupIII (P < 0.05) after extubation.

We found that using esmolol before extubation following coronary arterybypass graft surgery prevents undesirable haemodynamic responses whilemagnesium reduces undesirable haemodynamic responses but does not preventthem.